Cargando…

Safety Profile of a Virus-Like Particle-Based Vaccine Targeting Self-Protein Interleukin-5 in Horses

Background: Insect bite hypersensitivity (IBH) is an eosinophilic allergic dermatitis of horses caused by type I/IVb reactions against mainly Culicoides bites. The vaccination of IBH-affected horses with equine IL-5 coupled to the Cucumber mosaic virus-like particle (eIL-5-CuMV(TT)) induces IL-5-spe...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonsdottir, Sigridur, Fettelschoss, Victoria, Olomski, Florian, Talker, Stephanie C., Mirkovitch, Jelena, Rhiner, Tanya, Birkmann, Katharina, Thoms, Franziska, Wagner, Bettina, Bachmann, Martin F., Kündig, Thomas M., Marti, Eliane, Fettelschoss-Gabriel, Antonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349629/
https://www.ncbi.nlm.nih.gov/pubmed/32397549
http://dx.doi.org/10.3390/vaccines8020213
_version_ 1783557099002789888
author Jonsdottir, Sigridur
Fettelschoss, Victoria
Olomski, Florian
Talker, Stephanie C.
Mirkovitch, Jelena
Rhiner, Tanya
Birkmann, Katharina
Thoms, Franziska
Wagner, Bettina
Bachmann, Martin F.
Kündig, Thomas M.
Marti, Eliane
Fettelschoss-Gabriel, Antonia
author_facet Jonsdottir, Sigridur
Fettelschoss, Victoria
Olomski, Florian
Talker, Stephanie C.
Mirkovitch, Jelena
Rhiner, Tanya
Birkmann, Katharina
Thoms, Franziska
Wagner, Bettina
Bachmann, Martin F.
Kündig, Thomas M.
Marti, Eliane
Fettelschoss-Gabriel, Antonia
author_sort Jonsdottir, Sigridur
collection PubMed
description Background: Insect bite hypersensitivity (IBH) is an eosinophilic allergic dermatitis of horses caused by type I/IVb reactions against mainly Culicoides bites. The vaccination of IBH-affected horses with equine IL-5 coupled to the Cucumber mosaic virus-like particle (eIL-5-CuMV(TT)) induces IL-5-specific auto-antibodies, resulting in a significant reduction in eosinophil levels in blood and clinical signs. Objective: the preclinical and clinical safety of the eIL-5-CuMV(TT) vaccine. Methods: The B cell responses were assessed by longitudinal measurement of IL-5- and CuMV(TT)-specific IgG in the serum and plasma of vaccinated and unvaccinated horses. Further, peripheral blood mononuclear cells (PBMCs) from the same horses were re-stimulated in vitro for the proliferation and IFN-γ production of specific T cells. In addition, we evaluated longitudinal kidney and liver parameters and the general blood status. An endogenous protein challenge was performed in murine IL-5-vaccinated mice. Results: The vaccine was well tolerated as assessed by serum and cellular biomarkers and also induced reversible and neutralizing antibody titers in horses and mice. Endogenous IL-5 stimulation was unable to re-induce anti-IL-5 production. The CD4(+) T cells of vaccinated horses produced significantly more IFN-γ and showed a stronger proliferation following stimulation with CuMV(TT) as compared to the unvaccinated controls. Re-stimulation using E. coli-derived proteins induced low levels of IFNγ(+)CD4(+) cells in vaccinated horses; however, no IFN-γ and proliferation were induced following the HEK-eIL-5 re-stimulation. Conclusions: Vaccination using eIL-5-CuMV(TT) induces a strong B-cell as well as CuMV(TT)-specific T cell response without the induction of IL-5-specific T cell responses. Hence, B-cell unresponsiveness against self-IL-5 can be bypassed by inducing CuMV(TT) carrier-specific T cells, making the vaccine a safe therapeutic option for IBH-affected horses.
format Online
Article
Text
id pubmed-7349629
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73496292020-07-14 Safety Profile of a Virus-Like Particle-Based Vaccine Targeting Self-Protein Interleukin-5 in Horses Jonsdottir, Sigridur Fettelschoss, Victoria Olomski, Florian Talker, Stephanie C. Mirkovitch, Jelena Rhiner, Tanya Birkmann, Katharina Thoms, Franziska Wagner, Bettina Bachmann, Martin F. Kündig, Thomas M. Marti, Eliane Fettelschoss-Gabriel, Antonia Vaccines (Basel) Article Background: Insect bite hypersensitivity (IBH) is an eosinophilic allergic dermatitis of horses caused by type I/IVb reactions against mainly Culicoides bites. The vaccination of IBH-affected horses with equine IL-5 coupled to the Cucumber mosaic virus-like particle (eIL-5-CuMV(TT)) induces IL-5-specific auto-antibodies, resulting in a significant reduction in eosinophil levels in blood and clinical signs. Objective: the preclinical and clinical safety of the eIL-5-CuMV(TT) vaccine. Methods: The B cell responses were assessed by longitudinal measurement of IL-5- and CuMV(TT)-specific IgG in the serum and plasma of vaccinated and unvaccinated horses. Further, peripheral blood mononuclear cells (PBMCs) from the same horses were re-stimulated in vitro for the proliferation and IFN-γ production of specific T cells. In addition, we evaluated longitudinal kidney and liver parameters and the general blood status. An endogenous protein challenge was performed in murine IL-5-vaccinated mice. Results: The vaccine was well tolerated as assessed by serum and cellular biomarkers and also induced reversible and neutralizing antibody titers in horses and mice. Endogenous IL-5 stimulation was unable to re-induce anti-IL-5 production. The CD4(+) T cells of vaccinated horses produced significantly more IFN-γ and showed a stronger proliferation following stimulation with CuMV(TT) as compared to the unvaccinated controls. Re-stimulation using E. coli-derived proteins induced low levels of IFNγ(+)CD4(+) cells in vaccinated horses; however, no IFN-γ and proliferation were induced following the HEK-eIL-5 re-stimulation. Conclusions: Vaccination using eIL-5-CuMV(TT) induces a strong B-cell as well as CuMV(TT)-specific T cell response without the induction of IL-5-specific T cell responses. Hence, B-cell unresponsiveness against self-IL-5 can be bypassed by inducing CuMV(TT) carrier-specific T cells, making the vaccine a safe therapeutic option for IBH-affected horses. MDPI 2020-05-09 /pmc/articles/PMC7349629/ /pubmed/32397549 http://dx.doi.org/10.3390/vaccines8020213 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jonsdottir, Sigridur
Fettelschoss, Victoria
Olomski, Florian
Talker, Stephanie C.
Mirkovitch, Jelena
Rhiner, Tanya
Birkmann, Katharina
Thoms, Franziska
Wagner, Bettina
Bachmann, Martin F.
Kündig, Thomas M.
Marti, Eliane
Fettelschoss-Gabriel, Antonia
Safety Profile of a Virus-Like Particle-Based Vaccine Targeting Self-Protein Interleukin-5 in Horses
title Safety Profile of a Virus-Like Particle-Based Vaccine Targeting Self-Protein Interleukin-5 in Horses
title_full Safety Profile of a Virus-Like Particle-Based Vaccine Targeting Self-Protein Interleukin-5 in Horses
title_fullStr Safety Profile of a Virus-Like Particle-Based Vaccine Targeting Self-Protein Interleukin-5 in Horses
title_full_unstemmed Safety Profile of a Virus-Like Particle-Based Vaccine Targeting Self-Protein Interleukin-5 in Horses
title_short Safety Profile of a Virus-Like Particle-Based Vaccine Targeting Self-Protein Interleukin-5 in Horses
title_sort safety profile of a virus-like particle-based vaccine targeting self-protein interleukin-5 in horses
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349629/
https://www.ncbi.nlm.nih.gov/pubmed/32397549
http://dx.doi.org/10.3390/vaccines8020213
work_keys_str_mv AT jonsdottirsigridur safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses
AT fettelschossvictoria safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses
AT olomskiflorian safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses
AT talkerstephaniec safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses
AT mirkovitchjelena safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses
AT rhinertanya safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses
AT birkmannkatharina safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses
AT thomsfranziska safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses
AT wagnerbettina safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses
AT bachmannmartinf safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses
AT kundigthomasm safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses
AT martieliane safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses
AT fettelschossgabrielantonia safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses